Non-financial boards have been closed but will continue to be accessible in read-only form. If you're disappointed, we understand. Thank you for being an active participant in this community. We have more community features in development that we look forward to sharing soon.
If Civica can do what it claims, and even get close on their proposed price, that will crash the marketplace for fast-acting insulin.Basal products such as Lantus, Basaglar, etc will take longer. Lantus is no longer protected by patents, but the production requirements are, as yet, not really known except to the companies.Trulicity, etc would be much longer still because they do fill a niche fast-acting insulin can not. And this class of drugs would have significant production costs even if there were no patents.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |